CIK 0001509261 · Non-accelerated filer<br>Smaller reporting company
Rezolute, Inc.
Sign in to watch- Ticker
- RZLT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Jun 30
- Incorporated
- NV
- Entity type
- operating
- EIN
- 273440894
- Phone
- 650-206-4507
- Business address
- 275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY, CA, 94065
- Former names
- AntriaBio, Inc., FITS MY STYLE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-10 | Elam Nevan C CEO | Grant or award | +68,000 | 292,119 | ||
| 2025-06-10 | Elam Nevan C CEO | Grant or award · Employee Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2025-03-31 | Hogenhuis Wladimir Director | Purchase | +6,758 | $2.92 | $20K | 84,025 |
| 2025-03-27 | Elam Nevan C CEO | Purchase | +12,302 | $2.85 | $35K | 224,119 |
| 2025-03-26 | Evans Daron CFO | Purchase | +10,000 | $2.89 | $29K | 237,900 |
| 2025-03-26 | Evans Daron CFO | Purchase | +10,000 | $2.88 | $29K | 23,000 |
| 2025-03-25 | Harris Erik Director | Grant or award · Director Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2025-02-18 | Hogenhuis Wladimir Director | Purchase | +10,000 | $4.70 | $47K | 77,267 |
| 2025-02-16 | Hogenhuis Wladimir Director | Grant or award | +25,500 | 67,267 | ||
| 2025-02-16 | Hogenhuis Wladimir Director | Grant or award · Director Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2025-02-16 | Labrucherie Gil M Director | Grant or award | +25,500 | 25,500 | ||
| 2025-02-16 | Labrucherie Gil M Director | Grant or award · Director Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2025-02-16 | Evans Daron CFO | Grant or award | +77,000 | 227,900 | ||
| 2025-02-16 | Evans Daron CFO | Grant or award · Employee Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2025-02-16 | KREHER NERISSA Director | Grant or award | +25,500 | 25,500 | ||
| 2025-02-16 | KREHER NERISSA Director | Grant or award · Director Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2025-02-16 | Kim Young-Jin Director | Grant or award | +25,500 | 140,950 | ||
| 2025-02-16 | Kim Young-Jin Director | Grant or award · Director Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2025-02-16 | ROBERTS BRIAN KENNETH Chief Medical Officer | Grant or award | +77,000 | 131,352 | ||
| 2025-02-16 | ROBERTS BRIAN KENNETH Chief Medical Officer | Grant or award · Employee Stock Option (Right to Buy) | +45,000 | 45,000 |
Page 4 of 14 · 279 trades